A股異動 | 道氏技術漲4% 目前公司已與多家鈉離子正極材料客户供貨
格隆匯2月21日丨道氏技術(300409.SZ)漲4.28%,報17.04元,總市值99億元。道氏技術接受機構調研時表示,目前公司已與多家鈉離子正極材料客户供貨。公司致力於開發高容量、高安全、低成本鈉離子電池正極材料前驅體技術,已成功開發全新鈉離子池正極材料前驅體體系。公司碳納米管漿料得到業內主流生產企業比亞迪股份有限公司、浙江南都電源動力股份有限公司、江西安馳新能源科技有限公司等客户的認可。現已批量供貨寧德時代新能源科技股份有限公司,進入中創新航科技股份有限公司、惠州億緯鋰能股份有限公司、珠海冠宇電池股份有限公司等企業的供應商體系。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.